Canaquest Launches Mentanine (R) (Cannabidiol + IP Formula) in the US via WWW.CANAQUESTSTORE.COM, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
CanaQuest Medical Corp (OTC PINK: CANQF) has launched its all-natural product, Mentanine®, in California, aimed at enhancing mental health. The formulation combines cannabidiol (CBD) with Omega-3s and is designed to cross the blood-brain barrier, showing effectiveness in tackling anxiety, depression, PTSD, and related conditions. Backed by pre-clinical trials published in the European Journal of Neuroscience, this product claims to improve mental clarity, sleep quality, and reduce joint stiffness. The announcement reflects CanaQuest's ongoing commitment to drug discovery within the endocannabinoid system.
- Launch of Mentanine® targeting mental health disorders.
- Formulation enhances bioavailability and crosses the blood-brain barrier.
- Supported by pre-clinical trials published in reputable journals.
- Endorsed by user testimonials indicating improved quality of life.
- None.
USERS REPORT INCREASED MENTAL CLARITY,
BETTER SLEEP, MORE ENERGY, AND LESS BRAIN FOG AND JOINT STIFFNESS
TORONTO, ON / ACCESSWIRE / September 8, 2022 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in California for distribution across the United States and international export.
Proprietary Formulation - IP protected, International Patents filed, and Pre-clinical Trial results - published in peer-reviewed European Journal of Neuroscience (Oct. 2020).
New Pathway Discovery - molecules bond and synergistically attach to Peroxisome proliferator-activated receptors (PPARs) allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trials.
Mentanine® was developed by Dr. Steven Laviolette, a neuroscientist and scientific veteran with decades of research experience in the field of mental health and cannabinoids. Dr. Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. www.laviolettelab.com
CanaQuest has further enhanced the formulation and delivery format for maximum bioavailability.
One user, a doctor, stated (without professional advice): "For the last seven years I had problems with sleeping, body pain and depression. I am so optimistic that from now and onward with Mentanine®, I have my normal happy life back."
"Mentanine® effectively reaches the section of the brain that regulates emotion, such as anxiety, depression, and PTSD. We believe our scientific formulation will materially improve quality of life for people suffering from certain debilitating mental health ailments," commented Paul Ramsay, CanaQuest Medical President.
- Physicians, psychiatrists, healthcare practitioners, and pharmacists interested in joining our growing network can contact paul@canaquest.com.
- Customers can register at info@canaqueststore.com for updates on product developments.
- CanaQuest welcomes discussions with domestic and international medical cannabinoid distributors. Please contact us with indications of interest.
CanaQuest Medical Corp
CanaQuest Medical is an award-winning, Clinical Stage/Life-Sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD," including addiction.The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist with over 20 years of experience in the field of mental health and cannabinoids at Western University. Dr. Laviolette and his team of 13 scientists made two amazing discoveries that are Drug Candidates targeting neurological conditions: Drug Candidate for epilepsy,CQ-001, is supported by (cannabidiol "CBD" + IP formula) - molecules bond and synergistically attach to PPAR receptors allowing CQ-001to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trials. The second Drug Candidate, CQ-002, supported by (cannabinoid "THC" + IP formula), is a safer alternative to all other THC products based on pre-clinical trial results.
CanaQuest was named: 2022 Global Excellence Awards Best Medical Cannabis and Botanical Oils Product Development Company, 2022 North America
- awarded by Global Health & Pharma, UK. https://www.ghp-news.com/about-us/
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" as defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs, and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual Disclosure Statement filed with the OTC Markets for the most recent fiscal year.
CANAQUEST CONTACT:
Paul Ramsay, President
CanaQuest Medical Corp
paul@canaquest.com
Tel: 416.704.3040
www.canaquest.com
www.canaqueststore.com
SOURCE: CanaQuest Medical Corp.
View source version on accesswire.com:
https://www.accesswire.com/715075/Canaquest-Launches-Mentanine-R-Cannabidiol-IP-Formula-in-the-US-via-WWWCANAQUESTSTORECOM-Supported-by-Western-University-Pre-Clinical-Trials-Targeting-Anxiety-Depression-and-PTSD
FAQ
What is Mentanine and how does it affect mental health?
What are the clinical trial results for Mentanine?
When was Mentanine launched in the US?
What is the significance of the formulation's ability to cross the blood-brain barrier?
How can healthcare practitioners get involved with CanaQuest?
